We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Refine your search

Content type
Firm name

87 results found


Nutter McClennen & Fish LLP | USA | 17 May 2010

Ground-breaking federal district court ruling on gene patents

In Association for Molecular Pathology et al. v. United States Patent And Trademark Office et al., Association for Molecular Pathology and other plaintiffs, including some physicians and cancer patients, asked a federal district court in New York, in a motion for summary judgment, to invalidate several so-called “gene patents” owned by the University of Utah and Myriad Genetics.


Duane Morris LLP | USA | 31 Mar 2010

District court invalidates claims to isolated DNA molecules and methods of their use; finds subject matter ineligible for patent protection

On March 29, 2010, in a ruling that may have a tremendous impact on the biotechnology community, the U.S. District Court for the Southern District of New York held that patent claims related to the BRAC1 and BRAC2 genes, as well as claims to methods of using nucleotide sequences within those genes to assess susceptibility to cancer, were invalid, in Association for Molecular Pathology v. USPTO, Myriad Genetics, et al. (Myriad).

Previous page 1 2 3 ...